Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

GSK Submits Pandemic Flu Vaccine Under EU Accelerated Review Program

This article was originally published in The Pink Sheet Daily

  • News
  • Kathleen Michael

Executive Summary

Submission marks the first use of the European Medicines Agency’s “core dossier” accelerated review program.

You may also be interested in...



GSK Vaccine Manufacturing Plan Alternates Pandemic And Seasonal Flu

Results from one of two Phase I pandemic flu vaccine trials in the third quarter will support accelerated European regulatory efforts.

GSK Vaccine Manufacturing Plan Alternates Pandemic And Seasonal Flu

Results from one of two Phase I pandemic flu vaccine trials in the third quarter will support accelerated European regulatory efforts.

EMEA Committee Agrees To Expedite Flu Vaccine Reviews

Accelerated review of flu vaccine “core dossiers” would allow approval within days of strain identification.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal

Deal Watch: Six Small Biopharma Mergers Reflect Recent Trend

BMS Fast Tracks CAR-T Manufacturing With Cellares Deal

Corbus And Janux Lead Q1’s Small-Cap Winners

See All
UsernamePublicRestriction

Register

PS063151

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By